-
Nuchal translucency measurements for first-trimester screening: The 'price' of inaccuracy.
Evans MI, Van Decruyes H, Nicolaides KH.
Fetal Diagn Ther 2007;22:401-404. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
Spencer K, Cowans NJ, Avgidou K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;28:637-43. -
Sonographic screening for trisomy 13 at 11 to 13(+6) weeks of gestation.
Papageorghiou AT, Avgidou K, Spencer K, Nix B, Nicolaides KH.
Am J Obstet Gynecol 2006;194:397-401. -
Cystic hygromas, nuchal edema, and nuchal translucency at 11-14 weeks of gestation.
Molina FS, Avgidou K, Kagan KO, Poggi S, Nicolaides KH.
Obstet Gynecol 2006;107:678-83. -
Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH.
Obstet Gynecol 2006;107:6-10. -
Fetal tricuspid regurgitation at the 11 + 0 to 13 + 6-week scan: association with chromosomal defects and reproducibility of the method.
Falcon O, Faiola S, Huggon I, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:609-12. -
Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
Ultrasound Obstet Gynecol 2006;27:151-5. -
Fetal nuchal translucency scan and early prenatal diagnosis of chromosomal abnormalities by rapid aneuploidy screening: observational study.
Chitty LS, Kagan KO, Molina FS, Waters JJ, Nicolaides KH.
BMJ 2006;332:452-5. -
Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness.
Vandecruys H, Faiola S, Auer M, Sebire N, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:551-3. -
The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
Spencer K, Cicero S, Atzei A, Otigbah C, Nicolaides KH.
Prenat Diagn 2005;25:927-9. -
Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations.
Spencer K, Heath V, El-Sheikhah A, Ong CY, Nicolaides KH.
Prenat Diagn 2005;25:365-9. -
Increased nuchal translucency with normal karyotype.
Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1005-21. -
First-Trimester Screening for Chromosomal Abnormalities.
Nicolaides KH.
Semin Perinatol 2005;29:190-4. -
Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O.
Ultrasound Obstet Gynecol 2005;25:221-6. -
Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21.
Nicolaides KH, Chervenak FA, McCullough LB, Avgidou K, Papageorghiou A.
Am J Obstet Gynecol 2005;193:322-6. -
Down syndrome screening marker levels in women with a previous aneuploidy pregnancy.
Cuckle HS, Spencer K, Nicolaides KH.
Prenat Diagn 2005;25:47-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies.
Avgidou K, Papageorghiou A, Bindra R, Spencer K, Nicolaides KH.
Am J Obstet Gynecol 2005;192:1761-7. -
Relation between nuchal translucency thickness and prevalence of major cardiac defects in fetuses with normal karyotype.
Atzei A, Gajewska K, Huggon IC, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;26:154-7. -
The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
Spencer K, Bindra R, Cacho AM, Nicolaides KH.
Prenat Diagn 2004;24:169-73.